The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Schmid
Christoph
C
Brändle
Michael
M
D000077465:Cabergoline; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000188:drug therapy*; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline